Cannabics Pharmaceuticals

99 articles with Cannabics Pharmaceuticals

• CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials

  11/4/2021

  Cannabics Pharmaceuticals Inc. announced today that it has signed an agreement with Purisys, a leading Active Pharmaceutical Iingredient (API) manufacturer, for supply of Good Manufacturing Practice (GMP) grade APIs required for the manufacturing of RCC-33, the company's colorectal cancer treatment drug candidate.

• Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors

  10/25/2021

  Cannabics Pharmaceuticals Inc. announced today that Dr. Yonina Tova (MD), internationally recognized Radiation Oncologist has joined the company's Board of Advisors.

• Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer

  10/18/2021

  Cannabics Pharmaceuticals Inc. announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.

• Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases

  9/21/2021

  Cannabics Pharmaceuticals Inc . announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental Health Diseases.

• Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

  9/13/2021

  Cannabics Pharmaceuticals Inc. announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined the company as Head of Psychedelic Inspired Medicine.

• Cannabics Pharmaceuticals Appoints a Second Independent Board Member

  7/20/2021

  Cannabics Pharmaceuticals Inc. announced today that it has appointed Dr. Gil Feiler to its Board of Directors as an Independent Director.

• Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

  7/7/2021

  Cannabics Pharmaceuticals Inc. announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an Independent Director.

• Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice

  6/28/2021

  Cannabics Pharmaceuticals Inc. released today the interim results of its second in-vivo POC study evaluating the efficacy of company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer on mice.

• Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

  6/17/2021

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases.

• Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program

  6/3/2021

  Cannabics Pharmaceuticals Inc., a global leader in the development of cancer related cannabinoid-based medicine, announced the launching of a new research program for the development of a Breast Cancer antitumor targeting medicine.

• The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology

  5/25/2021

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the company's patent titled: "System and Method for High Throughput Screening of Cancer Cells"  has been granted by the European Patent Office .

• Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations

  5/11/2021

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it had filed a patent application under the Patent Cooperation Treaty (PCT) for novel formulations developed for treatment of various cancer types.

• Cannabics Pharmaceuticals Receives Patent Notice of Allowance From The Mexican Patent and Trademark Office (IMPI)

  5/6/2021

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it had received "Notice of Allowance" from the Mexican Patent and Trademark Office (IMPI)  in relation to the company's patent titled: 'System and method for high throughout screening of cancer cells"

• 

  Sun's Out to Play, But So Is Skin Cancer - Here's What Pharma is Doing About It

  4/27/2021

  There are several experimental treatments undergoing study for types of melanoma. BioSpace rounds up some of the most recent clinical news in this space.

• Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program

  4/20/2021

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program using Psylocibin and Psilocin.

• Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33

  3/31/2021

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today it is initiating a Dose Response in-vivo Study in mice; results to be included as part of the Product Package to be submitted to the U.S. Food and Drug Administration

• Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

  3/17/2021

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the concluding results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice

• Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016

  2/17/2021

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, further clarifies with regards to the final study results released on February 16, 2021 ,

• Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

  2/16/2021

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice.

• Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

  2/3/2021

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for colorectal cance